Symbols / CELC
CELC Chart
About
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.02B |
| Enterprise Value | 4.76B | Income | -162.72M | Sales | — |
| Book/sh | 2.70 | Cash/sh | 9.83 | Dividend Yield | — |
| Payout | 0.00% | Employees | 87 | IPO | — |
| P/E | — | Forward P/E | -24.02 | PEG | — |
| P/S | — | P/B | 40.13 | P/C | — |
| EV/EBITDA | -29.89 | EV/Sales | — | Quick Ratio | 11.73 |
| Current Ratio | 12.26 | Debt/Eq | 273.89 | LT Debt/Eq | — |
| EPS (ttm) | -3.68 | EPS next Y | -4.52 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 | ROA | -26.60% |
| ROE | -122.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 46.27M |
| Shs Float | 24.67M | Short Float | 23.63% | Short Ratio | 12.91 |
| Short Interest | — | 52W High | 120.31 | 52W Low | 7.58 |
| Beta | 0.38 | Avg Volume | 794.78K | Volume | 24.59K |
| Target Price | $116.70 | Recom | Strong_buy | Prev Close | $105.79 |
| Price | $108.47 | Change | 2.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$116.70
Mean price target
2. Current target
$108.63
Latest analyst target
3. DCF / Fair value
$-35.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$108.63
Low
$94.00
High
$155.00
Mean
$116.70
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-12 | init | Wells Fargo | — → Overweight | $126 |
| 2025-12-02 | main | Jefferies | Buy → Buy | $134 |
| 2025-11-18 | init | Wolfe Research | — → Outperform | $110 |
| 2025-11-17 | down | HC Wainwright & Co. | Buy → Neutral | $94 |
| 2025-11-13 | main | Craig-Hallum | Buy → Buy | $108 |
| 2025-11-13 | main | Stifel | Buy → Buy | $115 |
| 2025-10-22 | main | HC Wainwright & Co. | Buy → Buy | $77 |
| 2025-10-20 | reit | Needham | Buy → Buy | $70 |
| 2025-10-03 | reit | Needham | Buy → Buy | $70 |
| 2025-09-22 | init | Guggenheim | — → Buy | $110 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $66 |
| 2025-08-15 | main | Needham | Buy → Buy | $70 |
| 2025-07-28 | main | Leerink Partners | Outperform → Outperform | $60 |
| 2025-07-28 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-07-28 | reit | Needham | Buy → Buy | $29 |
| 2025-06-30 | reit | Needham | Buy → Buy | $29 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-05-15 | reit | Needham | Buy → Buy | $29 |
| 2025-04-11 | reit | Needham | Buy → Buy | $29 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
- Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy? - simplywall.st Mon, 23 Feb 2026 12
- Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews Fri, 20 Feb 2026 19
- Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily Mon, 23 Feb 2026 19
- Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - Yahoo Finance Sun, 22 Feb 2026 19
- Celcuity Inc: A Die To Be Cast Before July 2026 (NASDAQ: CELC) - Seeking Alpha Fri, 23 Jan 2026 08
- Ex-Seagen oncology exec joins Celcuity board for breast cancer drug push - Stock Titan hu, 12 Feb 2026 08
- Celcuity: What’s Happening With CELC Stock? - Forbes ue, 29 Jul 2025 07
- $CELC stock is up 46% today. Here's what we see in our data. - Quiver Quantitative Mon, 20 Oct 2025 07
- Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise - Yahoo Finance ue, 24 Feb 2026 11
- Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator With 16.91% Potential Upside - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance Fri, 13 Feb 2026 08
- Celcuity Inc. (CELC) Stock Analysis: Exploring the Biotechnology Innovator’s Growth Potential - DirectorsTalk Interviews Fri, 23 Jan 2026 08
- Celcuity (CELC): Assessing Valuation Following Recent Share Price Surge - Yahoo Finance Fri, 28 Nov 2025 08
- Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance hu, 05 Feb 2026 08
- Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Yahoo Finance Mon, 02 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 215 | — | — | Stock Award(Grant) at price 0.00 per share. | ROMP CHARLES R | Director | — | 2026-02-11 00:00:00 | D |
| 1 | 20000 | 2400538 | — | Sale at price 120.03 per share. | DALVEY DAVID F | Director | — | 2026-01-27 00:00:00 | I |
| 2 | 19975 | — | — | Stock Gift at price 0.00 per share. | NIGON RICHARD J | Director | — | 2025-12-15 00:00:00 | D |
| 3 | 3000 | 317070 | — | Sale at price 105.34 - 106.04 per share. | BULLER RICHARD E | Director | — | 2025-12-05 00:00:00 | I |
| 4 | 3000 | 16500 | — | Conversion of Exercise of derivative security at price 5.50 per share. | BULLER RICHARD E | Director | — | 2025-12-05 00:00:00 | I |
| 5 | 250 | 1900 | — | Conversion of Exercise of derivative security at price 7.60 per share. | FURCHT LEO M.D. | Director | — | 2025-12-04 00:00:00 | D |
| 6 | 500 | — | — | Stock Gift at price 0.00 per share. | BULLER RICHARD E | Director | — | 2025-12-02 00:00:00 | I |
| 7 | 1100 | 107948 | — | Sale at price 98.13 per share. | BULLER RICHARD E | Director | — | 2025-12-01 00:00:00 | I |
| 8 | 1100 | 16313 | — | Conversion of Exercise of derivative security at price 14.83 per share. | BULLER RICHARD E | Director | — | 2025-12-01 00:00:00 | I |
| 9 | 15000 | 1500016 | — | Sale at price 100.00 per share. | DALVEY DAVID F | Director | — | 2025-11-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -101.37M | -58.31M | -38.05M | -28.04M |
| TotalUnusualItems | 0.00 | -263.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | -263.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -111.78M | -63.78M | -40.37M | -29.61M |
| ReconciledDepreciation | 129.95K | 142.77K | 210.92K | 303.24K |
| EBITDA | -101.37M | -58.31M | -38.05M | -28.04M |
| EBIT | -101.50M | -58.45M | -38.26M | -28.34M |
| NetInterestIncome | 1.49M | 2.45M | -978.95K | -1.25M |
| InterestExpense | 10.28M | 5.33M | 2.11M | 1.26M |
| InterestIncome | 11.77M | 7.78M | 1.13M | 13.26K |
| NormalizedIncome | -111.78M | -63.78M | -40.37M | -29.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -111.78M | -63.78M | -40.37M | -29.61M |
| TotalExpenses | 113.27M | 66.23M | 39.39M | 28.36M |
| TotalOperatingIncomeAsReported | -113.27M | -66.23M | -39.39M | -28.36M |
| DilutedAverageShares | 39.45M | 23.68M | 15.42M | 13.38M |
| BasicAverageShares | 39.45M | 23.68M | 15.42M | 13.38M |
| DilutedEPS | -2.83 | -2.69 | -2.64 | -2.21 |
| BasicEPS | -2.83 | -2.69 | -2.64 | -2.21 |
| DilutedNIAvailtoComStockholders | -111.78M | -63.78M | -40.37M | -29.61M |
| NetIncomeCommonStockholders | -111.78M | -63.78M | -40.37M | -29.61M |
| NetIncome | -111.78M | -63.78M | -40.37M | -29.61M |
| NetIncomeIncludingNoncontrollingInterests | -111.78M | -63.78M | -40.37M | -29.61M |
| NetIncomeContinuousOperations | -111.78M | -63.78M | -40.37M | -29.61M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -111.78M | -63.78M | -40.37M | -29.61M |
| OtherIncomeExpense | -263.00 | |||
| SpecialIncomeCharges | 0.00 | -263.00 | ||
| GainOnSaleOfPPE | 0.00 | -263.00 | ||
| NetNonOperatingInterestIncomeExpense | 1.49M | 2.45M | -978.95K | -1.25M |
| InterestExpenseNonOperating | 10.28M | 5.33M | 2.11M | 1.26M |
| InterestIncomeNonOperating | 11.77M | 7.78M | 1.13M | 13.26K |
| OperatingIncome | -113.27M | -66.23M | -39.39M | -28.36M |
| OperatingExpense | 113.27M | 66.23M | 39.39M | 28.36M |
| ResearchAndDevelopment | 104.20M | 60.59M | 35.29M | 25.76M |
| SellingGeneralAndAdministration | 9.06M | 5.64M | 4.10M | 2.60M |
| GeneralAndAdministrativeExpense | 9.06M | 5.64M | 4.10M | 2.60M |
| OtherGandA | 9.06M | 5.64M | 4.10M | 2.60M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.14M | 25.51M | 21.67M | 14.92M |
| ShareIssued | 37.14M | 25.51M | 21.67M | 14.92M |
| NetDebt | 75.21M | 6.37M | 10.41M | |
| TotalDebt | 97.95M | 37.45M | 35.24M | 14.89M |
| TangibleBookValue | 115.62M | 139.77M | 133.77M | 68.71M |
| InvestedCapital | 213.35M | 176.80M | 168.75M | 83.34M |
| WorkingCapital | 212.85M | 176.40M | 168.31M | 82.85M |
| NetTangibleAssets | 115.62M | 139.77M | 133.77M | 68.71M |
| CapitalLeaseObligations | 225.92K | 410.87K | 255.20K | 259.93K |
| CommonStockEquity | 115.62M | 139.77M | 133.77M | 68.71M |
| PreferredStockEquity | 318.00 | 854.00 | 1.12K | |
| TotalCapitalization | 213.35M | 176.80M | 168.75M | 83.34M |
| TotalEquityGrossMinorityInterest | 115.62M | 139.77M | 133.77M | 68.71M |
| StockholdersEquity | 115.62M | 139.77M | 133.77M | 68.71M |
| RetainedEarnings | -271.86M | -160.08M | -96.30M | -55.93M |
| AdditionalPaidInCapital | 387.44M | 299.82M | 230.05M | 124.62M |
| CapitalStock | 37.46K | 26.36K | 22.79K | 14.92K |
| CommonStock | 37.14K | 25.51K | 21.67K | 14.92K |
| PreferredStock | 318.00 | 854.00 | 1.12K | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 129.50M | 51.45M | 41.93M | 17.20M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 97.78M | 37.26M | 35.04M | 14.69M |
| LongTermDebtAndCapitalLeaseObligation | 97.78M | 37.26M | 35.04M | 14.69M |
| LongTermCapitalLeaseObligation | 53.97K | 225.92K | 61.00K | 64.22K |
| LongTermDebt | 97.73M | 37.04M | 34.98M | 14.63M |
| CurrentLiabilities | 31.72M | 14.19M | 6.88M | 2.51M |
| CurrentDebtAndCapitalLeaseObligation | 171.95K | 184.95K | 194.20K | 195.71K |
| CurrentCapitalLeaseObligation | 171.95K | 184.95K | 194.20K | 195.71K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.09M | 1.82M | 968.18K | 472.93K |
| PayablesAndAccruedExpenses | 27.46M | 12.18M | 5.72M | 1.84M |
| CurrentAccruedExpenses | 18.09M | 7.11M | 3.09M | 329.96K |
| Payables | 9.37M | 5.08M | 2.63M | 1.51M |
| AccountsPayable | 9.37M | 5.08M | 2.63M | 1.51M |
| TotalAssets | 245.12M | 191.22M | 175.70M | 85.91M |
| TotalNonCurrentAssets | 552.02K | 628.80K | 506.56K | 554.35K |
| NetPPE | 552.02K | 628.80K | 506.56K | 554.35K |
| AccumulatedDepreciation | -1.99M | -1.86M | -1.72M | -1.51M |
| GrossPPE | 2.54M | 2.49M | 2.23M | 2.06M |
| Leases | 302.58K | 302.58K | 302.58K | 302.85K |
| OtherProperties | 215.50K | 400.02K | 246.27K | 241.90K |
| MachineryFurnitureEquipment | 2.03M | 1.79M | 1.68M | 1.52M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 244.57M | 190.59M | 175.19M | 85.35M |
| OtherCurrentAssets | 841.33K | 281.36K | 351.07K | |
| CurrentDeferredAssets | 33.20K | 22.14K | ||
| PrepaidAssets | 7.03M | 8.92M | 6.25M | 744.69K |
| Receivables | 1.60M | 805.88K | 0.00 | 298.76K |
| OtherReceivables | 1.60M | 805.88K | ||
| TaxesReceivable | 203.66K | 298.76K | ||
| CashCashEquivalentsAndShortTermInvestments | 235.10M | 180.58M | 168.59M | 84.29M |
| OtherShortTermInvestments | 212.59M | 149.92M | 144.02M | 0.00 |
| CashAndCashEquivalents | 22.51M | 30.66M | 24.57M | 84.29M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -83.72M | -53.91M | -36.17M | -20.39M |
| RepaymentOfDebt | 0.00 | -2.45K | -5.85K | -5.81K |
| IssuanceOfDebt | 59.23M | 0.00 | 19.51M | 14.35M |
| IssuanceOfCapitalStock | 63.61M | 14.43M | 100.50M | 78.55M |
| CapitalExpenditure | -249.88K | -97.64K | -158.77K | -81.90K |
| InterestPaidSupplementalData | 7.59M | 3.27M | 1.26M | 694.53K |
| EndCashPosition | 22.51M | 30.66M | 24.57M | 84.29M |
| BeginningCashPosition | 30.66M | 24.57M | 84.29M | 11.64M |
| ChangesInCash | -8.15M | 6.09M | -59.71M | 72.65M |
| FinancingCashFlow | 138.39M | 64.91M | 120.33M | 93.04M |
| CashFlowFromContinuingFinancingActivities | 138.39M | 64.91M | 120.33M | 93.04M |
| NetOtherFinancingCharges | -227.41K | -48.52K | -17.89K | |
| ProceedsFromStockOptionExercised | 15.78M | 50.53M | 324.12K | 148.02K |
| NetCommonStockIssuance | 63.61M | 14.43M | 100.50M | 78.55M |
| CommonStockIssuance | 63.61M | 14.43M | 100.50M | 78.55M |
| NetIssuancePaymentsOfDebt | 59.23M | -2.45K | 19.50M | 14.34M |
| NetLongTermDebtIssuance | 59.23M | -2.45K | 19.50M | 14.34M |
| LongTermDebtPayments | 0.00 | -2.45K | -5.85K | -5.81K |
| LongTermDebtIssuance | 59.23M | 0.00 | 19.51M | 14.35M |
| InvestingCashFlow | -63.07M | -5.01M | -144.03M | -81.40K |
| CashFlowFromContinuingInvestingActivities | -63.07M | -5.01M | -144.03M | -81.40K |
| NetInvestmentPurchaseAndSale | -62.82M | -4.91M | -143.87M | 0.00 |
| SaleOfInvestment | 642.35M | 309.61M | 0.00 | |
| PurchaseOfInvestment | -705.16M | -314.53M | -143.87M | 0.00 |
| NetPPEPurchaseAndSale | -249.88K | -97.64K | -158.77K | -81.40K |
| SaleOfPPE | 0.00 | 500.00 | ||
| PurchaseOfPPE | -249.88K | -97.64K | -158.77K | -81.90K |
| OperatingCashFlow | -83.47M | -53.81M | -36.01M | -20.31M |
| CashFlowFromContinuingOperatingActivities | -83.47M | -53.81M | -36.01M | -20.31M |
| ChangeInWorkingCapital | 18.35M | 3.86M | -1.19M | 819.81K |
| ChangeInOtherWorkingCapital | -7.74K | |||
| ChangeInOtherCurrentAssets | 775.98K | -3.44M | -5.53M | |
| ChangeInPayablesAndAccruedExpense | 17.57M | 7.30M | 4.33M | 1.33M |
| ChangeInAccruedExpense | 13.26M | 4.87M | 3.26M | 28.28K |
| ChangeInInterestPayable | -142.93K | 0.00 | ||
| ChangeInPayable | 4.32M | 2.43M | 1.08M | 1.31M |
| ChangeInAccountPayable | 4.32M | 2.43M | 1.08M | 1.31M |
| ChangeInPrepaidAssets | -5.62M | -405.64K | ||
| ChangeInReceivables | 95.10K | -108.76K | ||
| OtherNonCashItems | 2.84M | 1.06M | 704.66K | 5.56M |
| StockBasedCompensation | 6.99M | 4.90M | 4.64M | 2.61M |
| DepreciationAmortizationDepletion | 129.95K | 142.77K | 210.92K | 303.24K |
| DepreciationAndAmortization | 129.95K | 142.77K | 210.92K | 303.24K |
| Depreciation | 129.95K | 142.77K | 210.92K | 303.24K |
| OperatingGainsLosses | 263.00 | |||
| GainLossOnSaleOfPPE | 0.00 | 263.00 | ||
| NetIncomeFromContinuingOperations | -111.78M | -63.78M | -40.37M | -29.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CELC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|